Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-17T23:20:17.307Z Has data issue: false hasContentIssue false

Chapter 4 - Paraneoplastic movement disorders

from Section II - Movement disorders in systemic disease

Published online by Cambridge University Press:  05 April 2014

By
Francesc Valldeoriola  and
Josep Dalmau
Edited by
Werner Poewe  and
Joseph Jankovic
Francesc Valldeoriola
Affiliation:
IDIBAPS-Hospital Clínic, Service of Neurology, University of Barcelona, Barcelona, Spain
Josep Dalmau
Affiliation:
Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA
Werner Poewe
Affiliation:
Medical University Innsbruck
Joseph Jankovic
Affiliation:
Baylor College of Medicine, Texas
Get access

Summary

Introduction

Paraneoplastic neurological syndromes are rare disorders of the central or peripheral nervous system that predominantly occur in patients with cancer, but cannot be ascribed to a direct invasion of the nervous system by the tumor, metastases, or side effects of oncological therapy. They are often associated with immune responses that cross-react with proteins expressed by both by the underlying tumor and neuronal tissue.

Paraneoplastic disorders frequently precede the cancer diagnosis. In these cases, features that suggest a movement disorder is possibly paraneoplastic include a recent, rapid or subacute, clinical onset, the presence of inflammatory changes in the CSF, and the identification of specific antineuronal antibodies in the serum or CSF (Titulaer et al. 2011). Once recognized, prompt identification and treatment of the tumor along with immunotherapy can result in neurological symptom improvement or stabilization.

For many years, the relevance of paraneoplastic etiologies in the field of movement disorders was considered to be low. Opsoclonus-myoclonus was one of the first syndromes recognized as a paraneoplastic movement disorder, but since opsoclonus is readily recognized by most physicians, specialists in movement disorders are rarely consulted for this syndrome. On the other hand, stiff person syndrome and its variants are well-characterized paraneoplastic syndromes in which specialists in movement disorders are frequently involved. Indeed, the differential diagnosis of this syndrome with other clinical disorders such as parkinsonism, rigidity, and dystonia has been an area of interest for clinicians in the last decade. This interest has increased recently with the discovery of a new category of paraneoplastic and autoimmune encephalitis associated with dyskinesias that are likely mediated by neuronal antibodies against cell surface and synaptic proteins. A substantial number of patients with these disorders develop behavioral and psychiatric disturbances in association with prominent motor abnormalities. Paraneoplastic chorea and atypical parkinsonism have also been reported in patients with antineuronal antibodies, and, in general, there have been many case reports in the last few years showing associations between cancer, movement disorders, and neuronal autoimmunity (Baizabal-Carvallo and Jankovic 2012). Different from the traditional approach of describing movement disorders in the context of specific paraneoplastic syndromes or antineuronal antibodies, this chapter reviews the paraneoplastic etiologies following a classification based on the movement disorders (see Table 4.1).

Type
Chapter
Information
Movement Disorders in Neurologic and Systemic Disease , pp. 39 - 51
Publisher: Cambridge University Press
Print publication year: 2014

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Adams, C., McKeon, A., Silber, M. H., Kumar, R. (2011). “Narcolepsy, REM sleep behavior disorder, and supranuclear gaze palsy associated with Ma1 and Ma2 antibodies and tonsillar carcinoma,” Arch. Neurol. 68: 521–4.CrossRefGoogle ScholarPubMed
Ahlskog, M. C., Kumar, N., Mauermann, M. L., and Klein, C. J. (2012). “IgM-monoclonal gammopathy neuropathy and tremor: A first epidemiologic case control study,” Parkinsonism Relat. Disord.18: 748–52.CrossRefGoogle ScholarPubMed
Albin, R. L., Bromberg, M. B., Penney, J. B., and Knapp, R. (1988). “Chorea and dystonia: a remote effect of carcinoma,” Mov. Disord. 3: 162–9.CrossRefGoogle ScholarPubMed
Baizabal-Carvallo, J. F. and Jankovic, J. (2012). “Movement disorders in autoimmune diseases,” Mov. Disord. 27: 935–46.CrossRefGoogle ScholarPubMed
Baizabal-Carvallo, J. F., Stocco, A., Muscal, E., and Jankovic, J. (2013). “The spectrum of movement disorders in children with anti-NMDA receptor encephalitis,” Mov. Disord. (in press).CrossRef
Barnett, M., Prosser, J., Sutton, I., Halmagyi, G. M., Davies, L., Harper, C., et al. (2001). “Paraneoplastic brain stem encephalitis in a woman with anti-Ma2 antibody,” J. Neurol. Neurosurg. Psychiatry 70: 222–5.CrossRefGoogle Scholar
Bataller, L., Graus, F., Saiz, A., and Vilchez, J. J. (2001). “Spanish Opsoclonus-Myoclonus Study Group. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus,” Brain 124: 437–43.CrossRefGoogle ScholarPubMed
Batchelor, T. T., Platten, M., Palmer-Toy, D. E., Hunter, G. J., Lev, M. H., Dalmau, J., et al. (1998). “Chorea as a paraneoplastic complication of Hodgkin’s disease,” J. Neurooncol. 36: 185–90.CrossRefGoogle ScholarPubMed
Bernal, F., Shams’ili, S., Rojas, I., Sanchez-Valle, R., Saiz, A., Dalmau, J., et al. (2003). “Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin’s disease,” Neurology 60: 230–4.CrossRefGoogle ScholarPubMed
Blaes, F., Pike, M. G., and Lang, B. (2008). “Autoantibodies in childhood opsoclonus-myoclonus syndrome,” J. Neuroimmunol. 201: 221–6.CrossRefGoogle ScholarPubMed
Blumenthal, D. T., Salzman, K. L., Digre, K. B., Jensen, R. L., Dunson, W. A., and Dalmau, J. (2006). “Early pathologic findings and long-term improvement in anti-Ma2-associated encephalitis,” Neurology 67: 146–9.CrossRefGoogle ScholarPubMed
Bürk, K., Wick, M., Roth, G., Decker, P., and Voltz, R. (2010). “Antineuronal antibodies in sporadic late-onset cerebellar ataxia,” J. Neurol. 257: 59–62.CrossRefGoogle ScholarPubMed
Castle, J., Sakonju, A., Dalmau, J., and Newman-Toker, D. E. (2006). “Anti-Ma2-associated encephalitis with normal FDG-PET: a case of pseudo-Whipple’s disease,” Nat. Clin. Pract. Neurol. 2: 566–72.CrossRefGoogle ScholarPubMed
Choe, C. H. and Gausas, R. E. (2012). “Blepharospasm and apraxia of eyelid opening associated with anti-Hu paraneoplastic antibodies: a case report,” Ophthalmology 119: 865–8.CrossRefGoogle ScholarPubMed
Clerinx, K., Breban, T., Schrooten, M., Leite, M. I., Vincent, A., Verschakelen, J., et al. (2011). “Progressive encephalomyelitis with rigidity and myoclonus: resolution after thymectomy,” Neurology 76: 303–4.CrossRefGoogle ScholarPubMed
Compta, Y., Iranzo, A., Santamaría, J., Casamitjana, R., and Graus, F. (2007). “REM sleep behavior disorder and narcoleptic features in anti-Ma2-associated encephalitis,” Sleep 30: 767–9.CrossRefGoogle ScholarPubMed
Compta, Y., Valldeoriola, F., Urra, X., Gómez-Ansón, B., Rami, L., Tolosa, E., et al. (2007). “Isolated frontal disequilibrium as presenting form of anti-Hu paraneoplastic encephalomyelitis,” Mov. Disord. 22: 736–8.CrossRefGoogle ScholarPubMed
Croteau, D., Owainati, A., Dalmau, J., and Rogers, L. R. (2001). “Response to cancer therapy in a patient with a paraneoplastic choreiform disorder,” Neurology 57: 719–22.CrossRefGoogle Scholar
Dalakas, M. C. (2008). “Advances in the pathogenesis and treatment of patients with Stiff Person Syndrome,” Curr. Neurol. Neurosci. Rep. 8: 45–55.CrossRefGoogle ScholarPubMed
Dalmau, J., Gleichman, A. J., Hughes, E. G., Rossi, J. E., Peng, X., Lai, M., et al. (2008). “Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies,” Lancet Neurol. 7: 1091–8.CrossRefGoogle ScholarPubMed
Dalmau, J., Graus, F., Villarejo, A., Posner, J. B., Blumenthal, D., Thiessen, B., et al. (2004). “Clinical analysis of anti-Ma2-associated encephalitis,” Brain 127: 1831–44.CrossRefGoogle ScholarPubMed
Dalmau, J., Lancaster, E., Martinez-Hernandez, E., Rosenfeld, M. R., and Balice-Gordon, R. (2011). “Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis,” Lancet Neurol. 10: 63–74.CrossRefGoogle ScholarPubMed
Dalmau, J. and Rosenfeld, M. R. (2008). “Paraneoplastic syndromes of the CNS,” Lancet Neurol. 7: 327–40.CrossRefGoogle ScholarPubMed
Dalmau, J., Tüzün, E., Wu, H. Y., Masjuan, J., Rossi, J. E., Voloschin, A., et al. (2007). “Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma,” Ann. Neurol. 61: 25–36.CrossRefGoogle ScholarPubMed
David, Y., Warner, E., Levitan, M., Sutton, D. M. S., Malkin, M. G., and Dalmau, J. (1996). “Autoimmune paraneoplastic cerebellar degeneration in ovarian carcinoma patients treated with plasmapheresis and immunoglobulin,” Cancer 78: 2153–6.3.0.CO;2-Y>CrossRefGoogle ScholarPubMed
Devos, D., Vuillaume, I., de Becdelievre, A., De Martinville, B., Dhaenens, C. M., Cuveillier, J. C., et al. (2006). “New syndromic form of benign hereditary chorea is associated with a deletion of TITF-1 and PAX-9 contiguous genes,” Mov. Disord. 21: 2237–40.CrossRefGoogle ScholarPubMed
Dietl, H. W., Pulst, S. M., Engelhardt, P., and Mehraein, P. (1982). “Paraneoplastic brainstem encephalitis with acute dystonia and central hypoventilation,” J. Neurol. 227: 229–38.CrossRefGoogle ScholarPubMed
Erlich, R., Morrison, C., Kim, B., Gilbert, M. R., and Alrajab, S. (2004). “ANNA-2: an antibody associated with paraneoplastic opsoclonus in a patient with large-cell carcinoma of the lung with neuroendocrine features: correlation of clinical improvement with tumor response,” Cancer Invest 22: 257–61.CrossRefGoogle Scholar
Essalmi, L., Meaux-Ruault, N., Hafsaoui, C., Gil, H., Curlier, E., and Dupond, J. L. (2007). “Stiff person syndrome with thymoma. Efficacy of thymectomy,” Rev. Med. Interne 28: 627–30.CrossRefGoogle ScholarPubMed
Fekete, R. and Jankovic, J. (2012). “Childhood stiff-person syndrome improved with rituximab,” Case Rep. Neurol. 4: 92–6.CrossRefGoogle ScholarPubMed
Florance, N. R., Davis, R. L., Lam, C., Szperka, C., Zhou, L., Ahmad, S., et al. (2009). “Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents,” Ann. Neurol. 66: 11–18.CrossRefGoogle ScholarPubMed
Geschwind, M. D., Tan, K. M., Lennon, V. A., Barajas, R. F., Haman, A., Klein, C. J., et al. (2008). “Voltage-gated potassium channel autoimmunity mimicking Creutzfeldt-Jakob disease,” Arch. Neurol. 65: 1341–6.CrossRefGoogle ScholarPubMed
Gilhuis, H. J., van Ommen, H. J., Pannekoek, B. J., and Sillevis Smitt, P. A. (2005). “Paraneoplastic orthostatic tremor associated with small cell lung cancer,” Eur. Neurol. 54: 225–6.CrossRefGoogle ScholarPubMed
Golbe, L. I., Miller, D. C., and Duvoisin, R. C. (1989). “Paraneoplastic degeneration of the substantia nigra with dystonia and parkinsonism,” Mov. Disord. 4: 147–52.CrossRefGoogle ScholarPubMed
Gras, D., Jonard, L., Roze, E., Chantot-Bastaraud, S., Koht, J., Motte, J., et al. (2012). “Benign hereditary chorea: phenotype, prognosis, therapeutic outcome and long term follow-up in a large series with new mutations in the TITF1/NKX2–1 gene,” J. Neurol. Neurosurg. Psychiatry 83(10): 956–62.CrossRefGoogle Scholar
Hutchinson, M., Waters, P., McHugh, J., Gorman, G., O’Riordan, S., Connolly, S., et al. (2008). “Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody,” Neurology 71: 1291–2.CrossRefGoogle ScholarPubMed
Iizuka, T., Sakai, F., Ide, T., Monzen, T., Yoshii, S., Iigaya, M., et al. (2008). “Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal,” Neurology 70: 504–11.CrossRefGoogle ScholarPubMed
Inzelberg, R. and Jankovic, J. (2007). “Are Parkinson disease patients protected from some but not all cancers?” Neurology 69: 1542–50.CrossRefGoogle Scholar
Inzelberg, R., Weinberger, M., and Gak, E. (2011). “Benign hereditary chorea: An update,” Parkinsonism Relat. Disord. 17: 301–7.CrossRefGoogle ScholarPubMed
Irani, S. R., Alexander, S., Waters, P., Kleopa, K. A., Pettingill, P., Zuliani, L., et al. (2010). “Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia,” Brain 133: 2734–48.CrossRefGoogle ScholarPubMed
Ishii, A., Hayashi, A., Ohkoshi, N., Matsuno, S., and Shoji, S. (2004). “Progressive encephalomyelitis with rigidity associated with anti-amphiphysin antibodies,” J. Neurol. Neurosurg. Psychiatry 75: 661–2.Google ScholarPubMed
Jankovic, J. (1985). “Progressive supranuclear palsy: paraneoplastic effect of bronchial carcinoma,” Neurology 35: 446–7.CrossRefGoogle ScholarPubMed
Jankovic, J. and Clarence-Smith, K. (2011). “Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders,” Expert Review of Neurotherapeutics 11: 1509–23.CrossRefGoogle ScholarPubMed
Kareus, S. A., Figueroa, K. P., Cannon-Albright, L. A., and Pulst, S. M. (2012). “Shared predispositions of parkinsonism and cancer: a population-based pedigree-linked study,” Arch. Neurol. 69: 1572–7.CrossRefGoogle ScholarPubMed
Kinirons, P., Fulton, A., Keoghan, M., Para Brennan, P., Farrell, M. A., and Moroney, J. T. (2003). “Paraneoplastic limbic encephalitis (PLE) and chorea associated with CRMP-5 neuronal antibody,” Neurology 61: 1623–4.CrossRefGoogle ScholarPubMed
Kiriyama, T., Hirano, M., Kitauchi, T., Saito, K., Kataoka, H., and Ueno, S. (2011). “A case of chemotherapy-responsive paraneoplastic rubral tremor,” Clin. Neurol. Neurosurg. 113: 693–5.CrossRefGoogle ScholarPubMed
Kirsten, A., Beck, S., Fuhlhuber, V., Kaps, M., Kreutz, T., Korfei, M., et al. (2007). “New autoantibodies in pediatric opsoclonus myoclonus syndrome,” Ann. N. Y. Acad. Sci. 1110: 256–60.CrossRefGoogle ScholarPubMed
Kleinig, T. J., Thompson, P. D., and Kneebone, C. S. (2009). “Chorea, transverse myelitis, neuropathy and a distinctive MRI: paraneoplastic manifestations of probable small cell lung cancer,” J. Clin. Neurosci. 16: 964–6.CrossRefGoogle Scholar
Koide, R., Shimizu, T., Koike, K., and Dalmau, J. (2007). “EFA6A-like antibodies in paraneoplastic encephalitis associated with immature ovarian teratoma: a case report,” J. Neurooncol. 81: 71–4.CrossRefGoogle ScholarPubMed
Kujawa, K. A., Niemi, V. R., Tomasi, M. A., Mayer, N. W., Cochran, E., and Goetz, C. G. (2001). “Ballistic-choreic movements as the presenting feature of renal cancer,” Arch. Neurol. 58: 1133–5.CrossRefGoogle ScholarPubMed
Kurokawa, T., Taniwaki, T., Arakawa, K., Kikuchi, H., Yao, T., Tanaka, K., et al. (2001). “A case of paraneoplastic cerebellar degeneration with resting tremor,” Rinsho Shinkeigaku 41: 24–30.Google ScholarPubMed
Lai, M., Huijbers, M. G. M., Lancaster, E., Graus, F., Bataller, L., Balice-Gordon, R., et al. (2010). “Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series,” Lancet Neurol. 9: 776–85.CrossRefGoogle ScholarPubMed
Lancaster, E. and Dalmau, J. (2012). “Neuronal autoantigens-pathogenesis, associated disorders and antibody testing,” Nat. Review Neurol. 8: 380–90.CrossRefGoogle ScholarPubMed
Lancaster, E., Huijbers, M. G. M., Bar, V., Boronat, A., Wong, A., Martinez-Hernandez, E., et al. (2011). “Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia,” Ann. Neurol. 69: 303–11.CrossRefGoogle ScholarPubMed
Landolfi, J.C. and Nadkarni, M. (2003). “Paraneoplastic limbic encephalitis and possible narcolepsy in a patient with testicular cancer: case study,” Neuro. Oncol. 5: 214–16.CrossRefGoogle Scholar
Levy, L. M., Levy-Reis, I., Fijii, M., and Dalakis, M. C. (2005). “Brain gamma aminobutyric acid changes in Stiff Person Syndrome,” Arch. Neurol. 62: 970–4.CrossRefGoogle ScholarPubMed
Luque, F. A., Furneaux, H. M., Ferziger, R., Rosenblum, M. K., Wray, S. H., Schold, S. C., et al. (1991). “Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer,” Ann. Neurol. 29: 241–51.CrossRefGoogle ScholarPubMed
Manto, M. U., Laute, M. A., Aguera, M., Rogemond, V., Pandolfo, M., and Honnorat, J. (2007). “Effects of anti-glutamic acid decarboxylase antibodies associated with neurological diseases,” Ann. Neuol. 61: 544–51.CrossRefGoogle ScholarPubMed
Martinaud, O., Guegan-Massardier, E., Iasci, L., Miret, N., Mihout, B., and Hannequin, D. (2005). “Anti-Ri paraneoplastic syndrome associated with ophthalmoplegia, blepharospasm and palilalia,” Rev. Neurol. (Paris). 161: 81–6.CrossRefGoogle ScholarPubMed
Martinková, J., Valkovic, P., and Benetin, J. (2009). “Paraneoplastic chorea associated with breast cancer,” Mov. Disord. 24: 2296–7.CrossRefGoogle ScholarPubMed
Mas, N., Saiz, A., Leite, M. I., Waters, P., Baron, M., Castaño, D., et al. (2011). “Antiglycine-receptor encephalomyelitis with rigidity,” J. Neurol. Neurosurg. Psychiatry 82: 1399–401.CrossRefGoogle ScholarPubMed
Mason, W. P., Graus, F., Lang, B., Honnorat, J., Delattre, J. Y., Valldeoriola, F., et al. (1997). “Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome,” Brain 120: 1279–300.CrossRefGoogle ScholarPubMed
Matsumoto, L., Yamamoto, T., Higashihara, M., Sugimoto, I., Kowa, H., Shibahara, J., et al. (2007). “Severe hypokinesis caused by paraneoplastic anti-Ma2 encephalitis associated with bilateral intratubular germcell neoplasm of the testes,” Mov. Disord. 22: 728–31.CrossRefGoogle Scholar
McKeon, A., Martinez-Hernandez, E., Lancaster, E., Matsumoto, J. Y., Harvey, R. J., McEvoy, K. M., et al. (2013). “Glycine receptor autoimmunity in Stiff-Man syndrome phenotypes,” JAMA Neurol. 70(1): 44–50.CrossRefGoogle Scholar
Meinck, H. M. and Thompson, P. D. (2002). “Stiff man syndrome and related conditions,” Mov. Disord. 17: 853–66.CrossRefGoogle ScholarPubMed
Muehlschlegel, S., Okun, M. S., Foote, K. D., Coco, D., Yachnis, A. T., and Fernandez, H. H., (2005). “Paraneoplastic chorea with leukoencephalopathy presenting with obsessive-compulsive and behavioral disorder,” Mov. Disord. 20: 1523–7.CrossRefGoogle ScholarPubMed
Pan, T., Zhu, J., Hwu, W. J., and Jankovic, J. (2012). “The role of alpha-synuclein in melanin synthesis in melanoma and dopaminergic neuronal cells,” PLoS One 367: 319–28.Google Scholar
Peterson, K., Rosenblum, M. K., Kotanides, H., and Posner, J. B. (1992). “Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients,” Neurology 42: 1931–7.Google ScholarPubMed
Pittock, S. J., Lucchinetti, C. F., and Lennon, V. A. (2003). “Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments,” Ann. Neurol. 53: 580–7.CrossRefGoogle ScholarPubMed
Pittock, S. J., Lucchinetti, C. F., Parisi, J. E., Benarroch, E. E., Mokri, B., Stephan, C. L., et al. (2005). “Amphiphysin autoimmunity: paraneoplastic accompaniments,” Ann. Neurol. 58: 96–107.CrossRefGoogle ScholarPubMed
Pittock, S. J., Parisi, J. E., McKeon, A., Roemer, S. F., Lucchinetti, C. F., Tan, K. M., et al. (2010). “Paraneoplastic jaw dystonia and laryngospasm with antineuronal nuclear autoantibody type 2 (anti-Ri),” Arch. Neurol. 67: 1109–15.CrossRefGoogle Scholar
Rojas, I., Graus, F., Keime-Guibert, F., Reñé, R., Delattre, J. Y., Ramón, J. M., et al. (2000). “Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies,” Neurology 55: 713–15.CrossRefGoogle ScholarPubMed
Salsano, E., Ciano, C., Romano, S., Cornelio, F., Di Donato, S., and Pareyson, D. (2006). “Propriospinal myoclonus with life threatening tonic spasms as paraneoplastic presentation of breast cancer,” J. Neurol. Neurosurg. Psychiatry 77: 422–4.CrossRefGoogle ScholarPubMed
Samii, A., Dahlen, D. D., Spence, A. M., Maronian, N. C., Kraus, E. E., and Lennon, V. A. (2003). “Paraneoplastic movement disorder in a patient with non-Hodgkin’s lymphoma and CRMP-5 autoantibody,” Mov. Disord. 18: 1556–8.CrossRefGoogle Scholar
Sansing, L. H., Tuzun, E., Ko, M. W., Baccon, J., Lynch, D. R., and Dalmau, J. (2007). “A patient with encephalitis associated with NMDA receptor antibodies,” Nat. Clin. Pract. Neurol. 3: 291–6.CrossRefGoogle ScholarPubMed
Shams’ili, S., Grefkens, J., De Leeuw, B., van den Bent, M., Hooijkaas, H., van der Holt, B., et al. (2003). “Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients,” Brain 126: 1409–18.CrossRefGoogle ScholarPubMed
Simonetti, F., Pergami, P., Aktipi, K. M., Giardini, G., Ceroni, M., Lattuada, P., et al. (1998). “Paraneoplastic “rubral” tremor: a case report,” Mov. Disord. 13: 612–14.CrossRefGoogle ScholarPubMed
Solà-Valls, N., Gaba, L., Muñoz, E., Mellado, B., Ribalta, T., Saiz, A., et al. (2012). “Paraneoplastic cerebellar degeneration associated with thymic germinoma,” J. Neurol. Sci. 15(320): 153–5.CrossRefGoogle Scholar
Sommer, C., Weishaupt, A., Brinkhoff, J., Biko, L., Wessig, C., Gold, R., et al. (2005). “Paraneoplastic stiff person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin,” Lancet Neurol. 365: 1406–11.CrossRefGoogle ScholarPubMed
Steele, J. C., Richardson, J. C., and Olszewski, J. (1964). “Progressive supranuclear palsy: a heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia,” Arch. Neurol. 10: 333–59.CrossRefGoogle ScholarPubMed
Tan, J. H., Goh, B. C., Tambyah, P. A., and Wilder-Smith, E. (2005). “Paraneoplastic progressive supranuclear palsy syndrome in a patient with B-cell lymphoma,” Parkinsonism Relat. Disord. 11: 187–91.CrossRefGoogle Scholar
Tani, T., Piao, Y., Mori, S., Ishihara, N., Tanaka, K., Wakabayashi, K., et al. (2000). “Chorea resulting from paraneoplastic striatal encephalitis,” J. Neurol. Neurosurg. Psychiatry 69: 512–15.CrossRefGoogle ScholarPubMed
Tate, E. D., Allison, T. J., Pranzatelli, M. R., and Verhulst, S. J. (2005). “Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome,” Pediatr. Oncol. Nurs. 22: 8–19.CrossRefGoogle ScholarPubMed
Titulaer, M. J., Soffietti, R., Dalmau, J., Gilhus, N. E., Giometto, B., Graus, F., et al. (2011). “Screening for tumours in paraneoplastic syndromes: report of an EFNS task force,” Eur. J. Neurol. 18: 19–e3.CrossRefGoogle ScholarPubMed
Tonomura, Y., Kataoka, H., Hara, Y., Takamure, M., Naba, I., Kitauti, T., et al. (2007). “Clinical analysis of paraneoplastic encephalitis associated with ovarian teratoma,” J. Neurooncol. 84: 287–92.CrossRefGoogle ScholarPubMed
Tremont-Lukats, I. W., Fuller, G. N., Ribalta, T., Giglio, P., and Groves, M. D. (2002). “Paraneoplastic chorea: case study with autopsy confirmation,” Neuro. Oncol. 4: 192–5.Google ScholarPubMed
Vernino, S., Tuite, P., Adler, C. H., Meschia, J. F., Boeve, B. F., Boasberg, P., et al. (2002). “Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung carcinoma,” Ann. Neurol. 51: 625–30.CrossRefGoogle ScholarPubMed
Vigliani, M. C., Honnorat, J., Antoine, J. C., Vitaliani, R., Giometto, B., Psimaras, D., et al. (2011). “Chorea and related movement disorders of paraneoplastic origin: the PNS EuroNetwork experience,” PNS EuroNetwork J. Neurol. 258: 2058–68.CrossRefGoogle ScholarPubMed
Voltz, R., Gultekin, S. H., Rosenfeld, M. R., Gerstner, E., Eichen, J., Posner, J. B., et al. (1999). “A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer,” N. Engl. J. Med. 10(340): 1788–95.CrossRefGoogle Scholar
Wessig, C., Klein, R., Schneider, M. F., Toyka, K. V., Naumann, M., and Sommer, C. (2003). “Neuropathology and binding studies in anti-amphiphysin associated stiff person syndrome,” Neurology 61: 195–8.CrossRefGoogle ScholarPubMed
Williams, D. R., de Silva, R., Paviour, D. C., Pittman, A., Watt, H. C., Kilford, L., et al. (2005). “Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson’s syndrome and PSP-parkinsonism,” Brain 128: 1247–58.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×